(216) 444-9393 awasaki disease is an t~ acute, febrile, multisystem disease that primarily affects infants and young children. The report serves as a reminder that the etiology of this disease is unknown. It also highlights some of the difficulties in diagnosing Kawasaki disease and raises questions regarding the treatment of children with Kawasaki disease.
Etiology
Despite extensive epidemiologic and microbiologic research, the cause of Kawasaki disease remains unknown.' Clinical and epidemiologic characteristics suggest an infectious agent, but no single microorganism has been convincingly implicated. In fact, it is likely that a variety of pathogens are capable of interacting with an immunologically susceptible host to produce the disease process. The lack of a clearly demonstrated etio-logic agent makes diagnosis difficult and hinders efforts to prevent the disease.
Diagnosis
With an unknown etiology and lacking a specific diagnostic test, Kawasaki disease presents a daunting challenge to the clinician.
Clinical criteria have been developed to aid in the diagnosis,3°4 and careful adherence to these guidelines permits accurate diagnosis in the majority of children with Kawasaki disease. A variety of associated symptoms and findings also alert the physician to the possibility of Kawasaki disease.5 5 However, atypical Kawasaki disease is welldescribed and increasingly recognized. 6 Atypical cases are those which do not fulfill the diagnostic criteria but in which coronary artery aneurysms or other pathognomonic findings develop. _ Another diagnostic problem is the patient with an alternative diagnosis, such as ¡3-hemolytic streptococcal infection, who develops concurrent or subsequent Kawasaki disease. Although the With an array of diagnostic difficulties, ranging from atypical or incomplete forms of the disease to a variety of mimicking pathogens, there exists a risk of delay in diagnosing the patient with Kawasaki disease. Such a delay in diagnosis leads to a delay in treatment and perhaps a missed opportunity to reduce the morbidity and permanent sequelae of the disease. Therefore, timely diagnosis of Kawasaki disease requires: 1) a high index of suspicion, 2) clinical acumen and attention to detail in the history and physical examination, and 3) 
Treatment
Because Kawasaki disease is a multisystem inflammatory process, strategies for treatment have employed anti-inflammatory agents. Aspirin has long been the mainstay of this treatment and in doses of 50 to 100 mg/kg/day is effective in reducing the inflammatory response.
Recent studies have demonstrated the effectiveness of intravenous gamma globulin in producing a rapid anti-inflammatory response and in decreasing the incidence of coronary abnormalities. Original efficacy studies employed a regimen of 400 mg/kg/day for four days.8 Recently, 1 g/kg9,'O or 2 g/kg,11 given as a single dose, have produced similar reductions in the incidence of coronary artery abnormalities, with an improvement in clinical response. Single-dose regimens have the added advantage of a shorter hospital stay.
Although in the United States a consensus has developed regarding the use of intravenous gamma globulin to treat acute Kawasaki disease, questions remain regarding its use in patients with established coronary artery lesions and more than 10 days after the onset of the fever. 12 Both late treatment and treatment in patients with established coronary disease remain controversial. In fact, it has been ironically suggested that diagnostic difficulties and the tendency to treat aggressively will eventually lead to the treatment of 150% of patients with Kawasaki disease in the United States. Research projects are in progress to identify those children with Kawasaki dis-ease at greatest risk for the development of coronary artery aneurysms. If Current treatment recommendations include aspirin (50 to 100 mg/kg/day in four divided doses) and intravenous gamma globulin (one dose of 2 g/kg) . Unfortunately, the evidence suggests that, despite this treatment, 6% to 12% of patients will develop coronary artery abnormalities. The potential for future adverse coronary events in these children, as well as the unknown effects of subclinical inflammation on coronary arteries of other children with Kawasaki disease, serve as a stimulus for investigators seeking specific causes and treatments for Kawasaki disease.
